Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects (18 to 70 years of age, inclusive) must have a diagnosis of HS for at least~  1 year prior to Baseline~* Stable HS for at least 2 months prior to Screening and also at the Baseline Visit~* Inadequate response to at least a 3-month study of an oral antibiotic for treatment of HS~* Total abscess and inflammatory nodule count \>=3 at the Baseline Visit~* Subject must agree to daily use (and throughout the entirety of the study) of 1 pre-specified over-the-counter topical antiseptics on their HS lesions~* Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose~* Male subjects must be willing to use a method of contraception when sexually active, up till 20 weeks after the last administration of study medication~Exclusion Criteria:~* Prior treatment with anti-IL17s or participation in an anti-IL17 study~* Previously received anti-TNFs~* Subject requires, or is expected to require, opioid analgesics for any reason (excluding tramadol)~* Subject received prescription topical therapies for the treatment of HS within 14 days prior to the Baseline Visit~* Subject received systemic non-biologic therapies for HS with potential therapeutic impact for HS less than 28 days prior to Baseline Visit~* Draining fistula count \>20 at the Baseline Visit~* Diagnosis of inflammatory conditions other than HS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Bimekizumab (Type: EXPERIMENTAL): Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.
- Adalimumab (Type: ACTIVE_COMPARATOR): Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive several placebo applications to keep the blinding.

Based on this trial design, predict the completion outcome and termination type (if applicable).